

# Jurisdiction Specific Medicare Part B

## Dysport

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Dysport	abobotulinumtoxin A

### Covered Uses

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- Cervical dystonia
- Spasticity
- Blepharospasm
- Hemifacial spasm
- Isolated oromandibular dystonia

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

### Exclusions

Coverage will not be provided for cosmetic use.

# Coverage Criteria

## Cervical Dystonia

Authorization of 12 months may be granted for the treatment of adults with cervical dystonia.

## Spasticity

Authorization of 12 months may be granted for the treatment of spasticity in members 2 years of age and older.

## Blepharospasm

Authorization of 12 months may be granted for the treatment of blepharospasm in adults.

## Hemifacial spasm

Authorization of 12 months may be granted for hemifacial spasm (cranial nerve VII disorder) in adults.

## Isolated oromandibular dystonia

Authorization of 12 months may be granted for the treatment of isolated oromandibular dystonia in adults.

# Dosage and Administration

The lowest effective dose and longest dosing interval that produces the desired clinical effect should be used.

# References

1. Botulinum Toxins LCD (L33274) Version R11. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed August 5, 2024.
2. Billing and Coding: Botulinum Toxins (A57715) Version R10. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed August 5, 2024.
3. Dysport [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; September 2023.